of research and
development
scientific foundations
preferred MedMisti™ over a traditional spacer in early usability testing
aerosol generation with tunable particle control
Existing inhalation systems often force compromises between usability, dose consistency, formulation compatibility and effective delivery.
Mesh systems can block. Traditional devices can waste medication. Some depend heavily on patient coordination. Sensitive formulations may be exposed to heat, shear or inconsistent aerosol generation.
Misti® is taking a different approach.
Its acoustofluidic technology uses high-frequency sound waves to generate a controlled aerosol without relying on a mesh. MedMisti™ combines this technology with breath detection, precise liquid cartridges and connected-use tracking.
The platform is being developed to support:
MedMisti™ is the first real-world application.
The product proves the pathway. The platform creates the scale.
Misti® is no longer at the idea stage.
The scientific foundation has been established. Early product development, usability work, intellectual-property activity and commercial planning are underway. But several defining decisions still sit ahead.
The next development stage will shape:
Once those decisions are locked, the opportunity to influence them narrows.
Partners engaging now may be able to contribute to the evidence, capability and commercial structure required to move MedMisti™ towards market.
The value of early engagement is not access alone. It is influence.
Misti® is building from a substantial scientific and technical foundation.
The underlying platform is grounded in more than 10 years of research in surface acoustic wave nebulisation, acoustofluidics and pulmonary delivery.
Its scientific foundation includes peer-reviewed research examining respirable aerosol generation and the delivery of sensitive biological materials.
Internal aerosol characterisation has reported an MMAD of approximately 2–4 µm, a GSD of 1.1 and a fine-particle fraction above 90% under defined test conditions.
The platform is also being developed to tune particle size for different pulmonary-delivery requirements.
A pre-pilot usability study at the University of Melbourne’s Digital Simulation Lab involved 15 caregivers and children aged 8–14.
Reported results included:
Misti’s work has been supported through relationships across Australian research, engineering and medtech ecosystems, including the University of Melbourne, the Melbourne Centre for Nanofabrication, ANFF, ANDHealth, MTPConnect and the Medical Device Partnering Program.
Development work also spans cartridge design, electronics integration, manufacturing feasibility, quality-system preparation and regulatory planning.
Advancing a regulated medical technology takes specialist expertise, infrastructure, access and disciplined execution.
Misti’s next priorities include:
The right partner can reduce development friction, strengthen evidence and accelerate the pathway from promising technology to deployable product.
For aligned investors seeking exposure to medtech, connected respiratory care and advanced therapeutic delivery.
Potential collaboration areas:
For pharmaceutical and biotech teams exploring pulmonary delivery for complex or sensitive formulations.
Potential collaboration areas:
For healthcare providers, respiratory clinics, hospitals and care networks interested in usability, evidence generation and care pathway design.
Potential collaboration areas:
For partners with capability in manufacturability, scale up, supply chain, distribution or market access.
Potential collaboration areas:
For government, public health, defence and strategic health agencies focused on access, system resilience and respiratory care deployment.
Potential collaboration areas:
The strongest partners bring more than a name, logo or introductory conversation.
Misti® is particularly interested in organisations that can contribute one or more of the following:
A strong partnership fit usually includes:
A clear strategic reason to engage
There is a defined commercial, clinical, investment or technical opportunity.
A capability that moves the pathway forward
The partner brings capital, evidence, expertise, infrastructure, access or market reach.
An understanding of regulated development
The organisation recognises that serious medical technology requires staged validation, risk management and disciplined execution.
Tell us what opportunity you see, what your organisation can contribute and where you believe the strongest alignment exists.
Misti® welcomes enquiries from:
The window to shape it is now.
Misti® is advancing from scientific foundation and early validation towards manufacturability, regulatory readiness and commercial deployment.
The next stage will be shaped by partners who bring the capital, expertise, access and conviction required to move pulmonary delivery forward.
Find answers about how MedMisti™ works and what it can do for you
Misti® is currently seeking aligned investment and strategic partners to support the next stage of development, including usability testing, manufacturability, quality system planning, regulatory readiness, technical benchmarking, drug partnership development and go to market preparation.
Misti® is opening its next development round to aligned investors and strategic partners. Detailed funding information should be shared through the Expression of Interest process, investor deck or approved data room rather than relying only on public website copy.
The current funding pathway is intended to support human factors testing, proof of concept manufacturing, design refinement, technical benchmarking, IP expansion, quality management system setup, health economics modelling, drug partnership development and go to market preparation.
Misti® may be relevant to medtech investors, pharmaceutical and biotech companies, healthcare providers, respiratory clinics, public health organisations, government agencies, manufacturing partners, distribution partners and strategic healthcare organisations.
Yes. Misti® may support pharmaceutical and biotech partners exploring pulmonary delivery for biologics, RNA based medicines, inhaled vaccines, antibiotics, antivirals and other complex formulations that require controlled and formulation conscious delivery.
Potentially, yes. Strategic partners who engage during this stage may be able to contribute to use case selection, evidence requirements, formulation fit, clinical pathway design, market access planning and commercial model development.
Submit an Expression of Interest through the partnership form, outlining your organisation, role, area of interest and preferred type of engagement. Misti® can then assess alignment with the current development stage and future partnership pathway.
